Skip to main content
Erschienen in: Calcified Tissue International 5/2019

05.09.2019 | Original Research

Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature

verfasst von: Chang Liu, Zhen Zhao, Ou Wang, Mei Li, Xiaoping Xing, Evelyn Hsieh, Seiji Fukumoto, Yan Jiang, Weibo Xia

Erschienen in: Calcified Tissue International | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Autosomal dominant hypophosphatemic rickets (ADHR) is a rare hereditary disorder characterized by variant onset ages and diverse phenotypes. Our aim is to explore the genotype–phenotype correlations between ADHR patients with R176 and R179 mutations in FGF23 gene. Clinical manifestations, laboratory examinations, and genetic analyses were collected from 20 patients in six Chinese ADHR kindreds in our hospital. Previously published ADHR literatures were reviewed. Among 20 Chinese ADHR mutation carriers, 11 patients revealed overt symptoms. 10/11 (90.9%) of which were females. Patients with R179 mutations presented with earlier onset than those with R176 mutation [1.3 (1.0, 37.0) years vs. 28.5 (19.0, 44.0) years]. More patients with R179 mutations had a history of rickets with lower extremity deformity [3/4 (75%) vs. 1/7 (14.3%), p < 0.05]. The serum phosphate, i-FGF23 and c-FGF23 levels of patients with R179 and R176 mutations were 0.47 ± 0.14 mmol/L versus 0.57 ± 0.17 mmol/L, 79.6 ± 87.0 pg/mL versus 79.9 ± 107.4 pg/mL, and 33.4 ± 3.0 RU/mL versus 121.3 ± 177.6 RU/mL, respectively. 7/11 of patients had iron deficiency at onset of disease. When combined with previously reported seven ADHR families, difference was observed in the age of onset among symptomatic patients with R179 and R176 mutations [1.0 (0.9, 37.0) years vs. 24.5 (1.2, 57.0) years, p < 0.05]. Patients with R179 mutation were more likely to have rickets than R176 mutation (11/13, 84.6% vs. 5/20, 25.0%, p < 0.01) and lower extremity deformity (10/13, 76.9% vs. 6/19, 31.6%, p < 0.01). ADHR patients with R179 mutations had earlier onset age and more rickets compared to those with mutations in R176, which partially explained the clinical heterogeneity of ADHR.
Literatur
1.
Zurück zum Zitat Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681CrossRefPubMed Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681CrossRefPubMed
2.
Zurück zum Zitat Econs MJ, McEnery PT, Lennon F, Speer MC (1997) Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100:2653–2657CrossRefPubMedPubMedCentral Econs MJ, McEnery PT, Lennon F, Speer MC (1997) Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100:2653–2657CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Imel EA, Hui SL, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526CrossRefPubMed Imel EA, Hui SL, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526CrossRefPubMed
4.
Zurück zum Zitat Consortium A (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef Consortium A (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef
5.
Zurück zum Zitat Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben CI, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A (2010) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111–115CrossRefPubMed Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben CI, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A (2010) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111–115CrossRefPubMed
6.
Zurück zum Zitat Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849CrossRefPubMed Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849CrossRefPubMed
7.
Zurück zum Zitat White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed
8.
Zurück zum Zitat Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7:287–295PubMed Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7:287–295PubMed
9.
Zurück zum Zitat Seton M, Jüppner H (2013) Autosomal dominant hypophosphatemic rickets in an 85 year old woman: characterization of her disease from infancy through adulthood. Bone 52:640–643CrossRefPubMed Seton M, Jüppner H (2013) Autosomal dominant hypophosphatemic rickets in an 85 year old woman: characterization of her disease from infancy through adulthood. Bone 52:640–643CrossRefPubMed
10.
Zurück zum Zitat Tournis S, Koromila T, Chatzistamatas N, Droggaris M, Zafeiris C, Makris K, Marketou H, Papaioannou N, Kollia P, Gazi S (2013) Hip fracture leading to the diagnosis of autosomal dominant hypophosphatemic rickets. A case report. J Musculoskel Neuron 13:391–393 Tournis S, Koromila T, Chatzistamatas N, Droggaris M, Zafeiris C, Makris K, Marketou H, Papaioannou N, Kollia P, Gazi S (2013) Hip fracture leading to the diagnosis of autosomal dominant hypophosphatemic rickets. A case report. J Musculoskel Neuron 13:391–393
11.
Zurück zum Zitat Kruse K, Woelfel D, Strom TM (2001) Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res 55:305–308PubMed Kruse K, Woelfel D, Strom TM (2001) Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res 55:305–308PubMed
12.
Zurück zum Zitat Negri AL, Negrotti T, Alonso G, Pasqualini T (2004) Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family. Medicina 64:103–106PubMed Negri AL, Negrotti T, Alonso G, Pasqualini T (2004) Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family. Medicina 64:103–106PubMed
13.
Zurück zum Zitat Kapelari K, Köhle J, Kotzot D, Högler W (2015) Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets. J Clin Endocrinol Metab 100:3388–3392CrossRefPubMed Kapelari K, Köhle J, Kotzot D, Högler W (2015) Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets. J Clin Endocrinol Metab 100:3388–3392CrossRefPubMed
14.
Zurück zum Zitat Sun Y, Wang O, Xia W, Jiang Y, Li M, Xing X, Hu Y, Liu H, Meng X, Zhou X (2012) FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets. J Bone Miner Metab 30:78–84CrossRefPubMed Sun Y, Wang O, Xia W, Jiang Y, Li M, Xing X, Hu Y, Liu H, Meng X, Zhou X (2012) FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets. J Bone Miner Metab 30:78–84CrossRefPubMed
15.
Zurück zum Zitat Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310CrossRefPubMed Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310CrossRefPubMed
16.
Zurück zum Zitat Jiang Y, Xia W, Xing X, Silva BC, Li M, Wang O, Zhang H, Li F, Jing H, Zhong D, Jin J, Gao P, Zhou L, Qi F, Yu W, Bilezikian JP, Meng X (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27:1967–1975CrossRefPubMed Jiang Y, Xia W, Xing X, Silva BC, Li M, Wang O, Zhang H, Li F, Jing H, Zhong D, Jin J, Gao P, Zhou L, Qi F, Yu W, Bilezikian JP, Meng X (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27:1967–1975CrossRefPubMed
17.
Zurück zum Zitat Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis[J]. J Bone Miner Res 18:1227–1234CrossRefPubMed Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis[J]. J Bone Miner Res 18:1227–1234CrossRefPubMed
18.
Zurück zum Zitat Li H, Ji C, Zong X, Zhang Y (2009) Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years [J]. Chin J Pediatr 47:487–492 (In Chinese) Li H, Ji C, Zong X, Zhang Y (2009) Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years [J]. Chin J Pediatr 47:487–492 (In Chinese)
19.
Zurück zum Zitat Benet-Pagès A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455–462CrossRefPubMed Benet-Pagès A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455–462CrossRefPubMed
20.
Zurück zum Zitat Kato K, Jeanneau C, Tarp MA, Benet-Pagès A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Polypeptide Clausen H (2006) GalNAc-transferase T3 and familial tumoral calcinosis secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370–18377CrossRefPubMed Kato K, Jeanneau C, Tarp MA, Benet-Pagès A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Polypeptide Clausen H (2006) GalNAc-transferase T3 and familial tumoral calcinosis secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370–18377CrossRefPubMed
21.
Zurück zum Zitat Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, Koller A, Nizet V, White KE, Dixon JE (2014) Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 111:5520–5525CrossRefPubMed Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, Koller A, Nizet V, White KE, Dixon JE (2014) Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 111:5520–5525CrossRefPubMed
22.
Zurück zum Zitat Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774CrossRefPubMed Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774CrossRefPubMed
23.
Zurück zum Zitat Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, Moe OW, Liang G, Li X, Mohammadi M (2018) α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553(7689):461CrossRefPubMedPubMedCentral Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, Moe OW, Liang G, Li X, Mohammadi M (2018) α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553(7689):461CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Pettifor JM, Thandrayen K (2012) Hypophosphatemic rickets: unraveling the role of FGF23. Calcif Tissue Int 91:297–306CrossRefPubMed Pettifor JM, Thandrayen K (2012) Hypophosphatemic rickets: unraveling the role of FGF23. Calcif Tissue Int 91:297–306CrossRefPubMed
25.
Zurück zum Zitat Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed
26.
Zurück zum Zitat Clinkenbeard EL, Farrow EG, Summers LJ, Cass TA, Roberts JL, Bayt CA, Lahm T, Albrecht M, Allen MR, Peacock M, White KE (2014) Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR Mice. J Bone Miner Res 29:361–369CrossRefPubMedPubMedCentral Clinkenbeard EL, Farrow EG, Summers LJ, Cass TA, Roberts JL, Bayt CA, Lahm T, Albrecht M, Allen MR, Peacock M, White KE (2014) Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR Mice. J Bone Miner Res 29:361–369CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108:1146–1155CrossRef Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108:1146–1155CrossRef
28.
Zurück zum Zitat Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541–3549CrossRefPubMedPubMedCentral Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541–3549CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Durham BH, Joseph F, Bailey LM, Fraser WD (2007) The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 44:463–466CrossRefPubMed Durham BH, Joseph F, Bailey LM, Fraser WD (2007) The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 44:463–466CrossRefPubMed
30.
Zurück zum Zitat Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182CrossRefPubMed Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182CrossRefPubMed
31.
Zurück zum Zitat Carrillo-López N, Román-García P, Rodríguez-Rebollar A, Fernández-Martín JL, Naves-Díaz M, Cannata-Andía JB (2009) Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol 20:2009–2017CrossRefPubMedPubMedCentral Carrillo-López N, Román-García P, Rodríguez-Rebollar A, Fernández-Martín JL, Naves-Díaz M, Cannata-Andía JB (2009) Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol 20:2009–2017CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA (2011) Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the heart and soul study. Am J Kidney Dis 58:737–745CrossRefPubMedPubMedCentral Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA (2011) Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the heart and soul study. Am J Kidney Dis 58:737–745CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Holmlund-Suila E, Viljakainen H, Ljunggren Ö, Hytinantti T, Andersson S, Mäkitie O (2016) Fibroblast growth factor 23 concentrations reflect sex differences in mineral metabolism and growth in early infancy. Horm Res Paediat 85:232–241CrossRef Holmlund-Suila E, Viljakainen H, Ljunggren Ö, Hytinantti T, Andersson S, Mäkitie O (2016) Fibroblast growth factor 23 concentrations reflect sex differences in mineral metabolism and growth in early infancy. Horm Res Paediat 85:232–241CrossRef
34.
Zurück zum Zitat Holmlund-Suila E, Enlund-Cerullo M, Valkama SL, Hauta-Alus H, Rosendahl J, Helve O, Hytinantti T, Viljakainen H, Andersson S, Mäkitie O (2017) Sex and iron modify fibroblast growth factor 23 (FGF23) concentration in 1-year-old children. J Clin Endocrinol Metab 102:4526–4533CrossRefPubMed Holmlund-Suila E, Enlund-Cerullo M, Valkama SL, Hauta-Alus H, Rosendahl J, Helve O, Hytinantti T, Viljakainen H, Andersson S, Mäkitie O (2017) Sex and iron modify fibroblast growth factor 23 (FGF23) concentration in 1-year-old children. J Clin Endocrinol Metab 102:4526–4533CrossRefPubMed
35.
Zurück zum Zitat El-Maouche D, Dumitrescu CE, Andreopoulou P, Gafni RI, Brillante BA, Bhattacharyya N, Fedarko NS, Collins MT (2016) Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporosis Int 27:2345–2353CrossRef El-Maouche D, Dumitrescu CE, Andreopoulou P, Gafni RI, Brillante BA, Bhattacharyya N, Fedarko NS, Collins MT (2016) Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporosis Int 27:2345–2353CrossRef
Metadaten
Titel
Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature
verfasst von
Chang Liu
Zhen Zhao
Ou Wang
Mei Li
Xiaoping Xing
Evelyn Hsieh
Seiji Fukumoto
Yan Jiang
Weibo Xia
Publikationsdatum
05.09.2019
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 5/2019
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-019-00597-y

Weitere Artikel der Ausgabe 5/2019

Calcified Tissue International 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.